Creative Biolabs Expands Complement Assays and Adds Immunology, Microfluidic Capabilities for Biotherapeutics Research
核心洞察
Creative Biolabs (搜索) has expanded its complement assay portfolio to support preclinical development of next-generation complement therapeutics, adding C3b (搜索) deposition, hemolytic inhibition and individual component activity testing.
The company now offers integrated immunology services including anticomplementary activity assays and macrophage polarization analysis for characterizing antibodies, gene therapies and nanoparticles.
Customizable microfluidic solutions covering custom chip development aim to reduce reagent consumption and enable miniaturized, higher-throughput assays and dynamic cellular conditions.
Creative Biolabs (搜索) has expanded its complement assay service portfolio and integrated new immunology and microfluidic capabilities, aiming to support pharmaceutical and biotechnology researchers working with antibodies, gene therapies, nanoparticles and other biotherapeutic candidates.
Expanded Complement Assays Target Preclinical Development
Announced on August 20, 2026, the expanded complement assay portfolio is designed to help pharmaceutical and biotechnology companies accelerate development of next-generation complement therapeutics. According to the company, growing interest in complement-targeted drug discovery has increased demand for specialized functional assays, as researchers face challenges related to complex biological pathways, assay optimization, target validation and the need for reproducible data to guide development decisions.
The company states that without robust evaluation methods, identifying promising candidates and understanding their biological effects can become time-consuming and resource-intensive.
Among the expanded offerings, the C3b (搜索) deposition assay measures C3b deposition, described as a critical marker within the complement cascade, to analyze complement activation. The assay supports characterization of complement-targeting antibodies, proteins and other therapeutic candidates by providing quantitative data related to pathway regulation and biological activity.
Creative Biolabs (搜索) also provides a hemolytic inhibition assay to evaluate the ability of test candidates to inhibit complement-mediated cell lysis, supporting comparisons of candidate inhibitory activity under defined experimental conditions. In addition, individual components activity test services enable detailed analysis of specific complement proteins to support mechanism studies and pathway investigations.
The company positions these customizable solutions for research programs spanning early discovery and preclinical evaluation, with the goal of generating data that can inform candidate selection and optimization.
Immunology Assays Address Immune-Response Characterization
In a separate announcement dated September 15, 2026, Creative Biolabs (搜索) detailed integrated research capabilities spanning anticomplementary activity assessment, macrophage polarization analysis and customizable microfluidic solutions. The company notes that as biologic modalities diversify, researchers face increasingly complex questions surrounding immune-response characterization, functional assessment and experimental model selection, with complement-related effects, macrophage phenotypes and the need for more physiologically relevant models among the considerations influencing early-stage candidate evaluation.
The anticomplementary activity assay (ACA) service is intended to help researchers investigate complement-related effects and generate data for biotherapeutic characterization, formulation assessment and preclinical risk evaluation. The service can be tailored to different research needs, allowing scientists to incorporate complement assessment into broader immunological characterization workflows based on candidate type, study design and research objectives.
The macrophage polarization assay supports evaluation of M1/M2-associated phenotypes and polarization-related markers under different experimental conditions. Macrophages play roles in inflammation, tumor immunity, tissue remodeling and responses to therapeutic intervention, and characterizing their phenotypes can provide insight into immune mechanisms and treatment-associated cellular responses. The service is aimed at researchers studying immunomodulatory compounds, tumor microenvironments, inflammatory mechanisms and therapy-induced changes in macrophage function.
Microfluidics Extend Assay Flexibility
Alongside its immunology capabilities, Creative Biolabs (搜索) offers one-stop microfluidic solutions covering custom chip development and a range of microfluidic research applications. Microfluidic technologies allow researchers to manipulate small sample volumes within precisely controlled environments; depending on experimental objectives, these systems can help reduce reagent consumption, support miniaturized and higher-throughput assays, and enable dynamic cellular conditions that can be difficult to reproduce with conventional static culture approaches.
The company states that rather than relying on a one-size-fits-all approach, it works with researchers to select and customize experimental strategies according to specific therapeutic modalities, biological questions and study objectives. The combination of specialized immune assays and adaptable microfluidic technologies is intended to enable more flexible experimental workflows for investigating complex biological interactions while balancing sample requirements, assay throughput and data-generation needs.
Creative Biolabs (搜索) describes itself as a biotechnology research service provider serving pharmaceutical, biotechnology and academic organizations worldwide, with expertise in complement therapeutics, antibody development, protein engineering and specialized assay services.